Robert Gagel, MD, Chair: Dr. Gagel is a Professor of Medicine at MD Anderson Cancer Center where he served as Head of Endocrine Neoplasia and Head of Internal Medicine. He is a graduate of Ohio State University College of Medicine, did clinical training in Internal Medicine and Endocrinology and Metabolism at Tufts-New England Medical Center and a postdoctoral research fellowship at Harvard Medical School. He has been a faculty member at Baylor College of Medicine and MD Anderson Cancer Center. His major research accomplishments include a leadership role in the management of multiple endocrine neoplasia types 1 and 2, elucidation of the pathways by which mutations of the RET proto-oncogene cause medullary thyroid carcinoma and development of therapies based on this information, definition of the physiologic role of calcitonin and identification of mutations of the sulfonylurea receptor as the cause of persistent hypoglycemia of infancy.
Susan Greenspan, MD, Immediate Past President: Dr. Greenspan has held multiple roles at the University of Pittsburgh since 1999, including Professor of Medicine and Director of the Osteoporosis Prevention and Treatment Center. She is also the Director of the Bone Health Program at Magee Women’s Hospital and Program Director of the Clinical Translational Research Center at the University of Pittsburgh Medical Center. Dr. Susan Greenspan received her undergraduate degree from Stanford University and her MD from Harvard Medical School, where after training in Endocrinology and Geriatrics, she joined the faculty and founded and directed the Osteoporosis Center.
Dr. Greenspan’s NIH-funded research centers on osteoporosis in elderly men and women and has covered topics including new therapies for osteoporosis; new ways to diagnose, assess, and monitor bone loss; and bone loss in women with breast cancer and men with prostate cancer. Dr. Greenspan co-authored the U.S. Surgeon General’s report on Osteoporosis and has authored more than 150 peer reviewed articles and invited papers. She has served on the Scientific Advisory Boards for NOF and the International Society for Clinical Densitometry as well as several editorial boards of scientific journals. She was a council member of the American Society of Bone and Mineral Research from 2002-2005 and program chair for the 2006 annual meeting of the American Society of Bone and Mineral Research. She has also been featured in Best Doctors in America, Best Doctors in Pittsburgh and America’s Top Doctors.
Kenneth W. Lyles, MD, President: For the last 30 years, Dr. Lyles’ research and clinical career has focused on understanding the risk factors for impairment and disability and the consequences of the two most common metabolic bone diseases involving older patients; Osteoporosis and Paget’s Disease of Bone. With this knowledge he has attempted to develop novel therapies for these problems. His training and subsequent clinical practice as an Endocrinologist and a Geriatrician uniquely positions him to take advantage of the new technologies, risk assessment tools to diagnose these disorders and new drugs that reduce fractures and functional disability. He has designed and participated as Co-Principal Investigator in a clinical trial that demonstrated functional improvement in women with vertebral fractures using an exercise and quality of life intervention. His work in understanding the functional impairments associated with Paget Disease of Bone positioned him to help Novartis Pharmaceutical Corporation design and conduct a series of studies showing that intravenous zoledronic acid improved pain, function and bone remodeling in Paget patients. This work led the FDA to approve this drug to treat these patients. Now this agent is the drug of choice to treat the disorder because of its prolonged efficacy and safety. Finally, he and his colleagues were some of the first to describe the large re-fracture rate that occurs in all patients over age 50 years who sustain and recover from a low-trauma hip fracture repair. They used their finding to design and conduct the large international clinical trial using zoledronic acid to reduce the subsequent fracture rate after surgical repair of a hip fracture. They were also the first group to show that nitrogen-containing bisphosphonates had a positive effect on mortality in patients with osteoporosis. For the last four years he has observed and studied patients with Parkinson’s Disease and realized the tremendous burden and subsequent consequences of falls and fractures in the patients. Working closely with collaborators at the University of California San Francisco, Steven R. Cummings, MD, and Carlie Tanner, MD, PhD, they have designed, developed and have been awarded a novel in-home intervention with zoledronic acid to reduce the fracture rate and mortality in patients with Parkinson Disease. I his role as a clinician, Dr. Lyles treats patients with metabolic bone diseases at Duke University and VA Medical Centers.
Kathleen Shoemaker, Pharm. D., MBA, CPHIMS, Treasurer: Dr. Shoemaker is the Senior Director for Strategic Alliances at Premier, Inc. In this role, she works with professional medical societies and associations and Premier’s technology solutions for registry, reporting, learning management, and other services to meet these client’s strategic goals for quality, research, and education. Before Premier, Dr. Shoemaker was at the American Heart Association and was responsible for the strategic Health IT, quality measure, data, and registry development direction for AHA’s suite of quality and credentialing programs. Dr. Shoemaker came to AHA from Eli Lilly, where she worked with national quality organizations and alliances on mutually beneficial projects and policy. Dr. Shoemaker’s tenure at Lilly also included government payer strategy for Medicaid and Medicare Part D, and as an internal expert consultant for Medicare Part B, HIT strategy, payment models, and packaging/billing units. She enjoyed her preceptor role for Pharm D MBA students, taking on many of them for special projects for Lilly’s B2B organization. Dr. Shoemaker is a past Managed Care Pharmacy director and clinical manager at regional health plans. She has practiced extensively in both hospital and retail pharmacy as a pharmacist and immunizer.
Kathleen Shoemaker has a Doctor of Pharmacy from the University of Illinois, a master’s degree in Business Administration from Eastern Illinois University, and a bachelor’s degree in pharmacy from North Dakota State University. She is certified in Comparative Effective Research and is a Certified Professional in Health Information Management. She has published and presented in state and national venues.